BEIJING, August 19, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim ...
BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib ...
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...
BEIJING, Oct. 30, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...
When a biotech sells off rights to a promising new drug, investors have typically reacted positively to the news, welcoming the buyer's cash and the vote of confidence in the company's research. But ...
Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback